The assay monitors mutations across a patient's genome and matches them to mutations found in a patient's resected tumor and in DNA in the bloodstream.
The ALS Association is committing $3.5 million, including a $1 million commitment from its Greater New York chapter, while the Tow Foundation is contributing $2.5 million.
A study found that cis-regulatory variation modifies the penetrance of coding variants, and that variants' regulatory haplotype configuration affects disease risk.
